Zenodo (CERN European Organization for Nuclear Research)
December 18, 2021
Harriet A. Carroll
preprint
Background: Psychedelic drugs are increasingly being researched for their therapeutic properties in terms of treatment resistant mental illnesses. However, little is known about how they impact metabolism, which has implications for those with metabolic diseases such as diabetes. Hypohydration has been argued by some to cause glucose dysregulation, particularly due to elevations in arginine...
Journal of Psychopharmacology
December 13, 2021
Ben Sessa, Jacob S. Aday, Steve O’Brien et al.
18 citations
BACKGROUND: Incorporating 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy has shown promise in recent years for treating various mental health conditions, particularly those involving trauma. However, concerns about declines in mood and cognition during the days following dosing, also known as 'Blue Mondays', have been raised as limitations to its clinical use. Although...
Neurotoxicity Research
December 2021
Jan Van Amsterdam, Tibor M Brunt, Mimi Pierce et al.
Although MDMA (ecstasy) is a relatively safe recreational drug and is currently considered for therapeutic use for the treatment of posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD), recreational MDMA use occasionally elicits hyperthermia and hyponatremia, sometimes with a fatal outcome. Specific risk factors for both adverse effects are profuse sweating while vigorously...
Addictive Behaviors
December 1, 2021
G. Chan, Tianze Sun, Carmen C. W. Lim et al.
AIM To test the age, cohort, and period effect on past-year use trends in psychedelic drugs and ecstasy. METHOD Data were from a repeated cross-sectional nationally representative household survey in Australia conducted every three years between 2001 and 2019. An age-period-cohort model was used to test the effect of age, birth cohort, and period on past year psychedelic and ecstasy use....
Journal of Psychoactive Drugs
November 25, 2021
Tomislav Majić, Lasse Brandt, Christiane Montag
3 citations
3,4-methylenedioxymethamphetamine (MDMA/"ecstasy") is widespread in the electronic club scene, but MDMA has also been suggested for the treatment of anxiety spectrum disorders like posttraumatic stress disorder (PTSD) and social anxiety in autistic adults. Here, we report a case of a high functioning 24-old student with a sporadic recreational use of ecstasy, and a history of a single episode...
Frontiers in Psychology
November 11, 2021
Anne C Wagner
13 citations
MDMA's first identified potential as a therapeutic catalyst was for couple therapy. Early work in the 1970s and 1980s explored its potential amongst seasoned psychotherapists and their clients. With the completion of the first pilot trial of MDMA-assisted psychotherapy with couples for PTSD, and as the possibility of conducting MDMA-assisted psychotherapy trials expands due to new regulatory...
International Journal of Drug Policy
November 1, 2021
Amy Peacock, Daisy Gibbs, Olivia Price et al.
12 citations
Colorimetric reagent kits can provide information about the compounds present in drug samples. This study aimed to identify patterns and correlates of colorimetric reagent kit use, as well as behavioural outcomes of testing, amongst people who use illegal stimulants in a context that lacks permanent government-sanctioned drug checking services. Australians residing in capital cities who...
Alcoholism & Drug Abuse Weekly
October 29, 2021
Alison Knopf
Most patients with substance use disorder (SUD) also have anxiety, and many have post‐traumatic stress disorder (PTSD), using drugs or alcohol to self‐medicate (although not effectively). What happens with PTSD occurs in the amygdala, explained George Koob, Ph.D., director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), in an interview with ADAW last week. The emotional part...
The Journal of Clinical Pharmacology
October 28, 2021
K W Smith, Dakota Sicignano, Adrían V. Hernández et al.
136 citations
Abstract This article discusses current literature on the use of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy in the treatment of posttraumatic stress disorder (PTSD). MDMA, the intended active ingredient in illicit Ecstasy or Molly products, is a psychedelic that causes an elevated mood, feeling of bonding, and increased energy. In MDMA‐assisted psychotherapy, patients are...
PLoS One
October 25, 2021
Annie Regan, Seth Margolis, Harriet de Wit et al.
18 citations
3,4-Methylenedioxymethamphetamine (MDMA) is a psychostimulant known for producing positive subjective effects and for enhancing social functioning and social connection in both clinical and recreational settings. Over the past two decades, scientists have begun to study the psychological effects of MDMA through rigorous placebo-controlled experimental work. However, most existing studies have...